PKU HealthCareLtd Past Earnings Performance
Past criteria checks 5/6
PKU HealthCareLtd has been growing earnings at an average annual rate of 15.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 2.1% per year. PKU HealthCareLtd's return on equity is 8.4%, and it has net margins of 6.2%.
Key information
15.1%
Earnings growth rate
14.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -2.1% |
| Return on equity | 8.4% |
| Net Margin | 6.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How PKU HealthCareLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,073 | 129 | 361 | 27 |
| 30 Jun 24 | 2,118 | 99 | 430 | 29 |
| 31 Mar 24 | 2,189 | 72 | 514 | 29 |
| 31 Dec 23 | 2,194 | 44 | 575 | 28 |
| 30 Sep 23 | 2,176 | 56 | 600 | 22 |
| 30 Jun 23 | 2,160 | 57 | 637 | 19 |
| 31 Mar 23 | 2,094 | 60 | 642 | 16 |
| 01 Jan 23 | 2,077 | 56 | 652 | 15 |
| 30 Sep 22 | 2,100 | 34 | 680 | 1 |
| 30 Jun 22 | 2,134 | 40 | 699 | 0 |
| 31 Mar 22 | 2,207 | 32 | 740 | 15 |
| 01 Jan 22 | 2,237 | 43 | 782 | 14 |
| 30 Sep 21 | 2,279 | 56 | 832 | 22 |
| 30 Jun 21 | 2,254 | 50 | 842 | 23 |
| 31 Mar 21 | 2,127 | 52 | 817 | 8 |
| 31 Dec 20 | 1,977 | 39 | 789 | 9 |
| 30 Sep 20 | 2,139 | 45 | 803 | 13 |
| 30 Jun 20 | 2,198 | 44 | 800 | 16 |
| 31 Mar 20 | 2,385 | 45 | 828 | 17 |
| 31 Dec 19 | 2,509 | 50 | 841 | 16 |
| 30 Sep 19 | 2,461 | 51 | 789 | 12 |
| 30 Jun 19 | 2,394 | 47 | 755 | 7 |
| 31 Mar 19 | 2,278 | 46 | 726 | 5 |
| 31 Dec 18 | 2,316 | 45 | 716 | 6 |
| 30 Sep 18 | 2,147 | 43 | 701 | 9 |
| 30 Jun 18 | 2,159 | 40 | 651 | 10 |
| 31 Mar 18 | 2,210 | 42 | 598 | 9 |
| 31 Dec 17 | 2,146 | 34 | 501 | 8 |
| 30 Sep 17 | 2,345 | 27 | 451 | 2 |
| 30 Jun 17 | 2,240 | 22 | 412 | 0 |
| 31 Mar 17 | 2,127 | 13 | 359 | 0 |
| 31 Dec 16 | 2,070 | 13 | 338 | 0 |
| 30 Sep 16 | 1,733 | 226 | 332 | 0 |
| 30 Jun 16 | 1,956 | 159 | 375 | 0 |
| 31 Mar 16 | 1,956 | 118 | 402 | 0 |
| 31 Dec 15 | 2,011 | 25 | 426 | 0 |
| 30 Sep 15 | 2,074 | -269 | 412 | 0 |
| 30 Jun 15 | 2,018 | -189 | 368 | 0 |
| 31 Mar 15 | 2,193 | -135 | 346 | 0 |
| 31 Dec 14 | 2,266 | -27 | 321 | 0 |
| 30 Sep 14 | 2,456 | 57 | 301 | 0 |
| 30 Jun 14 | 2,388 | 62 | 298 | 0 |
| 31 Mar 14 | 2,276 | 65 | 288 | 0 |
| 31 Dec 13 | 2,316 | 78 | 285 | 0 |
Quality Earnings: 000788 has high quality earnings.
Growing Profit Margin: 000788's current net profit margins (6.2%) are higher than last year (2.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000788's earnings have grown by 15.1% per year over the past 5 years.
Accelerating Growth: 000788's earnings growth over the past year (130.5%) exceeds its 5-year average (15.1% per year).
Earnings vs Industry: 000788 earnings growth over the past year (130.5%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 000788's Return on Equity (8.4%) is considered low.